|Bid||101.59 x 800|
|Ask||101.79 x 900|
|Day's Range||100.89 - 102.99|
|52 Week Range||72.13 - 122.15|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||31.03|
|Forward Dividend & Yield||2.32 (2.26%)|
|Ex-Dividend Date||Sep 24, 2020|
|1y Target Est||N/A|
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the NIM Vital™ nerve monitoring system, which enables physicians to identify, confirm, and monitor nerve function to help reduce the risk of nerve damage during head and neck surgery.1 The NIM Vital system uses proprietary technology to provide detailed intraoperative nerve condition data that informs surgical strategy,2 increases operative efficiency and precision,3 and helps protect patients' quality of life.4
VANCOUVER, BC, Oct. 27, 2020 /CNW/ - Canadians from coast to coast to coast are taking action to tackle climate change in their communities.
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for the Abre™ venous self-expanding stent system. This device is indicated for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow obstruction, also known as deep venous obstruction.